Roivant unveils new ‘vant’ to take forward Bayer’s inhaled hypertension med

Matt Gline is back with a new ‘vant’ company, after the Roivant Sciences CEO paid Bayer $14 million upfront for the rights to a phase 2-ready pulmonary hypertension drug.

The asset in question, mosliciguat, is an inhaled soluble guanylate cyclase activator in development for pulmonary hypertension associated with interstitial lung disease (PH-ILD). As well as the upfront fee, Roivant has agreed to hand out up to $280 million in potential milestone payments to Bayer for the exclusive worldwide rights, on top of royalties.